Dodge & Cox Takes Position in Sanofi SA (SNY)
Dodge & Cox bought a new stake in Sanofi SA (NYSE:SNY) during the fourth quarter, according to its most recent disclosure with the SEC. The fund bought 68,508,540 shares of the company’s stock, valued at approximately $2,770,485,000. Sanofi SA makes up approximately 2.5% of Dodge & Cox’s holdings, making the stock its 11th largest position.
Several other large investors also recently bought and sold shares of the company. CKW Financial Group increased its stake in shares of Sanofi SA by 21.6% in the third quarter. CKW Financial Group now owns 2,816 shares of the company’s stock worth $108,000 after buying an additional 500 shares during the period. Menora Mivtachim Holdings LTD. acquired a new stake in shares of Sanofi SA during the fourth quarter worth about $109,000. JFS Wealth Advisors LLC increased its stake in shares of Sanofi SA by 1.9% in the third quarter. JFS Wealth Advisors LLC now owns 4,035 shares of the company’s stock worth $154,000 after buying an additional 74 shares during the period. FNY Partners Fund LP acquired a new stake in shares of Sanofi SA during the fourth quarter worth about $162,000. Finally, Jacobi Capital Management LLC increased its stake in shares of Sanofi SA by 31.9% in the third quarter. Jacobi Capital Management LLC now owns 4,271 shares of the company’s stock worth $164,000 after buying an additional 1,034 shares during the period. Hedge funds and other institutional investors own 9.63% of the company’s stock.
Sanofi SA (NYSE:SNY) traded up 0.4887% on Monday, reaching $44.5165. The company had a trading volume of 901,735 shares. Sanofi SA has a 12-month low of $36.81 and a 12-month high of $44.74. The stock has a market capitalization of $112.43 billion, a PE ratio of 23.2462 and a beta of 0.98. The stock’s 50 day moving average price is $42.61 and its 200-day moving average price is $40.26.
Sanofi SA (NYSE:SNY) last posted its earnings results on Wednesday, February 8th. The company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.01. Sanofi SA had a net margin of 13.66% and a return on equity of 26.37%. The business earned $8.88 billion during the quarter, compared to the consensus estimate of $9.87 billion. The company’s revenue for the quarter was down 4.3% on a year-over-year basis. Equities analysts expect that Sanofi SA will post $3.07 earnings per share for the current fiscal year.
The firm also recently disclosed an annual dividend, which will be paid on Wednesday, June 7th. Stockholders of record on Monday, May 15th will be given a dividend of $1.5771 per share. This is an increase from Sanofi SA’s previous annual dividend of $1.10. The ex-dividend date of this dividend is Thursday, May 11th. This represents a dividend yield of 3.65%. Sanofi SA’s payout ratio is presently 54.90%.
Your IP Address:
A number of brokerages recently issued reports on SNY. Liberum Capital began coverage on Sanofi SA in a research report on Thursday, March 9th. They issued a “hold” rating on the stock. Barclays PLC began coverage on Sanofi SA in a research report on Tuesday, March 7th. They issued an “underweight” rating on the stock. Zacks Investment Research downgraded Sanofi SA from a “buy” rating to a “hold” rating in a research report on Monday, February 13th. Natixis upgraded Sanofi SA from a “neutral” rating to a “buy” rating in a research report on Thursday, February 9th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Sanofi SA in a research report on Tuesday, January 10th. Two equities research analysts have rated the stock with a sell rating, nine have issued a hold rating and six have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $65.67.
Sanofi SA Company Profile
Sanofi SA, formerly Sanofi-Aventis, is a healthcare company engaged in the research, development, manufacture and marketing of therapeutic solutions. It operates through three segments: Pharmaceuticals, Human Vaccines (Vaccines) and Animal Health. The Pharmaceuticals segment consists of research, development, production and marketing of medicines, including those originating from Genzyme Corporation.
Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi SA (NYSE:SNY).
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with MarketBeat.com's FREE daily email newsletter.